Research Advances of Immunotherapy for Follicular Lymphoma --Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 627-630, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-928765
ABSTRACT
Follicular lymphoma is an indolent malignant tumor originating from lymph nodes and lymphoid tissues, which may affect the patients' quality of survival due to the recurrence and progression. In recent years, with the deepening understand of the molecular biology and signaling pathways, many new targeted drugs for follicular lymphoma have been discovered, such as monoclonal antibodies, checkpoint inhibitors, epigenetic regulation related targeted therapies and signaling pathway inhibitors. In this review, the new progress of immunotherapy for follicular lymphoma is summarized briefly.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Linfoma Folicular
/
Epigénesis Genética
/
Factores Inmunológicos
/
Inmunoterapia
/
Antineoplásicos
Límite:
Humanos
Idioma:
Chino
Revista:
Journal of Experimental Hematology
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS